A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A multicenter, open-label observational trial assessing the safety and effectiveness of LivaloZet® tablets in individuals with dyslipidemia and metabolic syndrome: Protocol for the PIVOT study

  • By

  • Kyong Hye Joung

  • Bon Jeong Ku

  • July 10, 2026

Share

  • 1

    The PIVOT study is a multicenter, observational trial assessing LivaloZet® tablets in Korean adults with dyslipidemia and metabolic syndrome.

  • 2

    The primary endpoint is the percent change in low-density lipoprotein cholesterol (LDL-C) from baseline at Week 24.

  • 3

    Secondary endpoints include LDL-C changes at Week 48 and changes in the full lipid panel and LDL-C target achievement rates.

  • 4

    Safety assessments will monitor adverse events, laboratory tests, and vital signs for statin-related hepatotoxicity and myopathy.

  • 5

    The study aims to provide real-world evidence on the effectiveness and safety of a pitavastatin/ezetimibe combination in this patient population.

Original Source(s)

A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol

  • by Kyong Hye Joung, Bon Jeong Ku

  • July 10, 2026

Related Content

Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.

Cardiac magnetic resonance imaging in patients referred for premature ventricular contractions: identifying patients most likely to benefit

Centers for Medicare & Medicaid Services to Launch Landmark ACCESS Program